Analysts upgraded SUNB, HAWK, and more, revising ratings and price targets.

Rocket Pharmaceuticals aligns with the FDA on key phase II study elements for RP-A501, advancing its

Analysts upgraded Similarweb, Rocket Pharmaceuticals, Radiant Logistics and Ulta Beauty; Paychex ros

Wedbush analyst Yun Zhong reiterates Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and m

As the Federal Reserve prepares to move on rates and oil prices surge past $105, Wednesday's top ana

Needham analyst Gil Blum upgrades Rocket Pharmaceuticals (NASDAQ:RCKT) from Hold to Buy and annou

Rocket Pharmaceuticals, Inc. (RCKT) Presents at Morgan Stanley 24th Annual Global Healthcare Confere

Rocket Pharmaceuticals, Inc. (RCKT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conf

[url="]Rocket Pharmaceuticals, Inc.[/url] (NASDAQ: RCKT), a fully integrated, commercial-stage biote

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, commercial-stage biotechnology compa

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, co

Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock?

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, co

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT - Get Free Report) has received a consensus rating of "Ho

RCKT records earnings growth in the second quarter. Kresladi launch preparations advance and RP-A501

Wedbush analyst Yun Zhong maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and lo

Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.37) per share which missed the

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, co

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) on Monday shared a clinical safety update concerning the

Rocket Pharmaceuticals announces positive early safety results for its RP-A501 Phase 2 trial in Dano

[url="]Rocket Pharmaceuticals, Inc.[/url] (Rocket or the Company) (NASDAQ: RCKT), a fully integrated

Initial three patients were treated safely; RP-A501 was well-tolerated with no TMA or capillary leak

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (Rocket or the Company) (NASDAQ: RCKT)

Gainers American Shared Hospital (AMEX:AMS) stock rose 14.2% to $1.61 during Wednesday's after-

The Rare Pediatric Disease Priority Review Voucher was granted by the FDA in March 2026 in connectio

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, co

Rocket Pharmaceuticals, Inc. (RCKT) Presents at Goldman Sachs 47th Annual Global Healthcare Conferen

Rocket Pharmaceuticals, Inc. (RCKT) Presents at Jefferies Global Healthcare Conference 2026 Transcri

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, co

Rocket Pharmaceuticals shares fell after a wider-than-expected Q1 loss as the company focuses on the

Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.42) per share which beat the a

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, co

Top analysts changed ratings for OVV, ALMS, CLMT, LGN, RCKT, UTHR, VNT, HOOD. See full changes at be

B of A Securities analyst Jason Zemansky maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Bu

Rocket Pharmaceuticals stock jumps after FDA nod for Kresladi in LAD-I; voucher sale may boost cash

First FDA-approved gene therapy for children with severe LAD-I due to biallelic variants in ITGB2Sev

https://www.sec.gov/Archives/edgar/data/1281895/000114036126008849/ny20066752x3_424b5.htm

Goldman Sachs analyst Richard Law maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Sell and

Cantor Fitzgerald analyst Josh Schimmer maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Ove

Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.38) per share which beat the a

B of A Securities analyst Jason Zemansky maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Bu

William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty i

FDA accepts Rocket Pharmaceuticals' resubmission for Kresladi gene therapy in severe LAD-I, with

Chardan Capital analyst Geulah Livshits maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy

Prescription Drug User Fee Act (PDUFA) target action date is March 28, 2026All primary and secondary

Leerink Partners analyst Mani Foroohar maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Mark